Danaher Corporation, a global science and technology company focusing on biotechnology, life sciences, and diagnostics, has a market cap of nearly $149 billion. While the stock has seen a decline of 7.8% over the past three months, it remains 13.8% below its January high. Danaher recently agreed to acquire Masimo Corporation for $180 per share in cash, strengthening its position in patient monitoring and specialty diagnostics. Analysts are bullish on Danaher, with a consensus rating of “Strong Buy” and an average price target of $264.05, implying a 26.2% upside potential.

Read more at Barchart: How Is Danaher Corporation’s Stock Performance Compared to other Health Care Stocks?